THE Therapeutic Goods
Administration is plotting a cull of
several senior staff, according to
the ABC which has cited a “leaked
internal document” which also
warns of increasing numbers of
counterfeit medicines.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 09 Mar 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Mar 16
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).